Principal Financial Group Inc. Reduces Stock Position in Henry Schein, Inc. $HSIC

Principal Financial Group Inc. reduced its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 15.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,145 shares of the company’s stock after selling 20,618 shares during the period. Principal Financial Group Inc.’s holdings in Henry Schein were worth $7,642,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. CYBER HORNET ETFs LLC bought a new position in Henry Schein in the 2nd quarter worth about $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter worth about $27,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Henry Schein in the second quarter valued at approximately $43,000. Evelyn Partners Investment Management Services Ltd purchased a new position in Henry Schein during the second quarter valued at approximately $62,000. Finally, Mather Group LLC. bought a new stake in Henry Schein during the 3rd quarter worth approximately $71,000. 96.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on HSIC. Evercore raised their price target on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Barclays began coverage on Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. JPMorgan Chase & Co. lifted their price target on Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Finally, Barrington Research set a $79.00 price objective on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $76.42.

Henry Schein Trading Down 0.3%

Shares of HSIC stock opened at $78.19 on Friday. The business has a 50-day moving average price of $77.09 and a two-hundred day moving average price of $71.28. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $82.80. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The firm has a market cap of $9.20 billion, a P/E ratio of 24.74, a price-to-earnings-growth ratio of 2.33 and a beta of 0.88.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.